You are here: Home
Health and Fitness
Diseases
Bristol-Myers Squibb Co. Losing Patent Protection for Three Drugs in the Next...
Bristol-Myers Squibb Co. Losing Patent Protection for Three Drugs in the Next Three Years
January 10, 2012 Diseases news in Houston,Texas, United States of America
The Center for the Biology of Chronic Disease (CBCD) has recently learned that Bristol-Myers Squibb Co. will lose patent protection for three of its top four drugs within the next three years.
FOR IMMEDIATE RELEASE
Houston,
Texas,
United States of America
(Free-Press-Release.com) January 10, 2012 --
The CBCD has learned that Bristol-Myers Squibb Co. will lose its patent on the blood thinner, Plavix this year. This could be quite a loss to the pharmaceutical giant since Plavix currently brings in $6.7 billion per year. In 2013 Bristol will lose its patent on the HIV drug, Sustiva which brings in around $1.4 billion. The company’s anti-psychotic drug, Abilify will become available for generic competition in 2015.
However, Bristol-Myers Squibb Co. recently purchased Inhibitex, Inc. for $2.5 billion and believes its investment in an oral drug to fight Hepatitis will help it to exceed 2010 revenues by 2020.
Les Funtleyder , a health-care strategist and portfolio manager with Miller Tabak & Co. in New York, wrote in an e-mail that “The world is moving toward an all-oral regimen for hepatitis C, and Bristol-Myers, which is strong in antivirals, seems like it wants to be a part of that.”
"Hepatitis" means inflammation of the liver. Toxins, certain drugs, some diseases, heavy alcohol use, and bacterial and viral infections can all cause hepatitis. Hepatitis is also the name of a family of viral infections that affect the liver; the most common types are Hepatitis A, Hepatitis B, and Hepatitis C.
Many viruses (including the Hepatitis C virus ) can infect the body and then begin storing dormant (sleeping) copies of themselves (imagine clone soldiers) somewhere in the body’s organs. In fact, the Hepatitis viruses are exactly these types of viruses. When the virus copies are latent, or dormant (asleep) they do nothing and the person has no symptoms even though the virus lives within the person’s body for life.
Moreover, the FDA says, “Some viruses…can enter a state known as latency in which the virus is not being replicated. In the latent state, the virus does not cause disease.”
However, many viruses can awaken and begin replicating themselves. Anyone who has had a fever blister or cold sore has experienced an awakening of the Herpes (HSV-1) virus within his or her system. The virus clones awaken and immediately begin attacking the body resulting in an Oral Herpes outbreak.
The same thing happens with many other viruses including the Hepatitis C virus. It invades and then settles into the body in a dormant, sleeping state…just waiting to wake up and attack the human system.
That is why the CBCD believes that more research into scientifically based, natural methods of combating dormant viruses is so important. It makes sense that methods for killing dormant viruses (including the dormant Hepatitis C virus) or boosting the immune system so that the human body eradicates viruses before they even become active, would be the best means of preventing diseases caused by viruses.
Some biotechnology companies such as polyDNA have stepped into this field of research and have come out with natural, Hepatitis C remedies such as Gene-Eden-Blue.
For more information on Gene-Eden-Blue and its effect on the dormant Hepatitis C virus, to learn how this Hepatitis remedy was developed without the use of animal testing, or to contact a polyDNA scientist for an interview, please visit the Gene-Eden-Blue website at http://www.hepatitis-remedy.com
For more information on the Center for the Biology of Chronic Disease, or to schedule an interview with one of our researchers, please visit http://www.cbcd.net or call 585-250-9999.
# # #
The Center for the Biology of Chronic Disease (CBCD, http://www.cbcd.net) is a research center recognized by the IRS as a 501(c)(3) non-for-profit organization. The mission of the CBCD is to advance the research on the biology of chronic diseases, and to accelerate the discovery of treatments for these diseases.
The CBCD published the “Purple” book by Dr. Hanan Polansky. The book presents Dr. Polansky’s highly acclaimed scientific theory on the relationship between the DNA of latent (chronic) viruses and the onset of chronic diseases. Dr. Polansky’s book is available as a free download from the CBCD website.
dormant virus HCV hepatitis C Hepatitis C Virus Hepatitis Remedy virus Viruses
People who viewed this press release also interested in the following topics: bristol-myers squibb.

Where: Jerusalem,Israel
Industry: Health & Beauty
Where: Vancouver, BC,Canada
Industry: Health & Beauty

Where: Poznan,Poland
Industry: Health & Beauty
Post your news to the World.See you news here immediately. It's easy and free!
Create free account or Login.



